Previous studies have suggested that the HIF transcription factors can both activate and inhibit gene expression. Here we show that HIF1 regulates the expression of mir-210 in a variety of tumor types through a hypoxia-responsive element. Expression analysis in primary head and neck tumor samples indicates that mir-210 may serve as an in vivo marker for tumor hypoxia. By Argonaute protein immunoprecipitation, we identified 50 potential mir-210 targets and validated randomly selected ones. The majority of these 50 genes are not classical hypoxia-inducible genes, suggesting mir-210 represses genes expressed under normoxia that are no longer necessary to adapt and survive in a hypoxic environment. When human head and neck or pancreatic tumor cells ectopically expressing mir-210 were implanted into immunodeficient mice, mir-210 repressed initiation of tumor growth. Taken together, these data implicate an important role for mir-210 in regulating the hypoxic response of tumor cells and tumor growth.
INTRODUCTION
Hypoxia, the condition of insufficient oxygen supply to tissues, results from a reduction in oxygen availability, inadequate oxygen transport, or the inability of the tissues to utilize oxygen. In normal tissues, high altitude exposure, anemia, and drugs can induce hypoxia-responsive pathways in the body. However, hypoxia is also a hallmark of cancer, where cancer cells shift their energy production from the TCA cycle to glycolysis (Kim and Dang, 2006) . The hypoxia-inducible factors (HIFs) are a family of transcription factors that have been identified as important regulators of the cellular response to hypoxia (Semenza, 1998) . Under normoxic conditions, the a subunit of HIF1 is hydroxylated at prolines 402 and 564 by prolyl-4-hydroxylases (PHDs), targeting HIF1a for proteasome destruction mediated by the von Hippel-Lindau (VHL) protein, an E3 ubiquitin ligase (Chan et al., 2005; Ivan et al., 2001; Jaakkola et al., 2001) . Under hypoxic conditions, the activity of PHDs decreases, HIF1a is stabilized and transcriptionally regulates a large number of target genes involved in adaptation and protection against low oxygen conditions (Chi et al., 2006) .
HIFs regulate an ever-increasing number of genes involved in glycolytic metabolism, angiogenesis, erythropoiesis, and metastasis (Chan and Giaccia, 2007; Semenza, 1998; Sullivan and Graham, 2007) . Recently, microRNAs (miRNAs) have emerged as a new class of noncoding genes involved in regulating cell proliferation, differentiation, and viability (Bartel, 2004; Stefani and Slack, 2008) . miRNAs are single-stranded small RNA molecules that are approximately 22 nucleotides in length. miRNAs primarily regulate gene expression through inhibition of RNA translation by base-pairing of their ''seed region,'' nucleotides 2-8, to their target genes' 3 0 UTR (Nilsen, 2007) . miRNAs can also facilitate targeting of specific mRNAs for cleavage, resulting in the downregulation of target mRNAs (Jackson and Standart, 2007; Lim et al., 2005) . It has been shown that miRNA expression is regulated by certain physiological stimuli (van Rooij et al., 2006) . We hypothesized that some miRNAs are regulated by hypoxia given the critical roles oxygen homeostasis plays in cellular physiology and the broad spectrum of genes hypoxia regulates. Several recent studies have shown that mir-210 is induced by hypoxia and appears to be a HIF target gene, although no identification of functional HREs have been demonstrated (Camps et al., 2008; Giannakakis et al., 2008; Kulshreshtha et al., 2007) .
In this report, we identified several hypoxia-regulated miRNAs through miRNA microarray analysis. We present evidence showing that one of the miRNAs, mir-210, is the predominant miRNA gene induced under hypoxic conditions in a broad spectrum of cancer types, and its transcriptional induction is HIF1a dependent. By immunoprecipitating the major functional component of the miRNA pathway, Argonaute 2 (AGO2), we identified a list of 50 genes as potential mir-210 targets, of which the majority are not known to be induced under hypoxia. The regulation of mir-210 by HIF can explain how HIF activation leads to inhibition of gene expression. Functionally, we show that ectopic expression of mir-210 represses tumor growth, linking HIF regulation to inhibition of tumor growth through mir-210 regulation.
RESULTS

mir-210 Is the Predominant Hypoxia-Inducible MicroRNA
To identify miRNA genes regulated by hypoxia, we analyzed the expression profiles of the human pancreatic cancer cell lines SU86.86 and PANC1 using a miRNA microarray containing 314, 49, and 14 probes corresponding to mature forms of human, mouse, and rat miRNAs, respectively. After 16 hr under 2% oxygen, paired nomoxia/hypoxia miRNA samples were labeled with either Cy3 or Cy5. In order to detect nonspecific labeling and hybridization, dye-swapped experiments were performed in parallel. Several miRNAs appeared to be robustly induced by hypoxia ( Figure 1A ), such as hsa-mir-328, mmumir-345, and hsa-mir-210. However, in the dye swap experiment, only the expression of hsa-mir-210 changed reciprocally ( Figure 1A ). Because HIF1a is a major regulator of the cellular response to hypoxia, we established a SU86.86 cell line that expresses a small hairpin RNA (shRNA) that reduces HIF1a expression to less than 10% of the wild-type controls ( Figure 1B) . After stable knockdown of HIF1a, the induction of mir-210 under hypoxia was undetectable ( Figure 1A ), which suggests that mir-210 is a HIF1a-regulated gene. Subsequent miRNA northern verification of the miRNA microarrays indicated that several other miRNA genes were also induced by hypoxia, although their induction was not as pronounced as mir-210 (see Figure S1 available online). For these reasons, mir-210 was chosen for further analysis in the present study.
Since it has been known that certain genes/pathways are activated under specific oxygen tensions, such as the unfolded protein response pathway (UPR), we investigated the inducibility of mir-210 under more stringent hypoxic conditions. As shown in Figure 1C , mir-210 is induced by mild as well as stringent oxygen tensions. Furthermore, the kinetics of mir-210 induction under 2% oxygen is similar to a classic hypoxia regulated gene, GLUT1 ( Figure 1D ). Taken together, our data suggest that mir-210 is highly responsive to changes in oxygen.
mir-210 Is Broadly Expressed and Is HIF1a Dependent
To investigate whether induction of mir-210 under hypoxia is tissue or cell-line specific, we examined the induction of mir-210 in pancreatic, breast, head and neck, lung, colon, and renal cell lines exposed to 2% oxygen for 24 hr by northern blotting. mir-210 was almost universally induced in all cell lines across different tissue origins (Figure 2A ). Generally, mir-210 expression was low under normoxic conditions, and its expression was greatly induced after exposure to hypoxia. Interestingly, in two pairs of renal cancer cell lines, RCC4/ RCC4-VHL and 786-O/786-VHL, mir-210 expression is clearly different (Figure 2A ). It is well-known that both RCC4 and 786-O harbor VHL gene mutations that in turn cause stabilization of HIF transcriptional factors. In RCC4 cells, both HIF1a and HIF2a are expressed, but in 786-O only HIF2a is expressed ( Figure 2B ). In addition, we possess a variant of the MDA-231 breast cancer cell line that has lost HIF1a expression ( Figure 2B ). Since both MDA-231 and 786-O cells exhibited poor mir-210 induction by hypoxia, this prompted us to determine whether mir-210 expression is HIF1 specific. In order to address the role of HIF1a versus HIF2a in mir-210 expression, siRNAs against HIF1a, HIF2a, or scramble control siRNAs were transfected into RCC4/VHL cell line. The cells transfected with siRNA scramble controls and siRNAs against HIF2a had robust induction of mir- Figure 2C ). Interestingly, the baseline expression of mir-210 was also reduced even under normoxic conditions, indicating that HIF1a also regulates the transcriptional expression of mir-210 under normoxia.
Characterization of mir-210 Promoter
HIF1a regulates target gene activity by binding to a hypoxia-responsive element (HRE) on genomic DNA. Since our data indicate that mir-210 is a HIF1a-regulated gene, we sought to determine how HIF1a regulates it. A 2.3 kb promoter sequence immediately upstream of mir-210 stem-loop structure was cloned into a pGL3-Basic vector ( Figure 3A) . By searching the 2.3 kb promoter sequence, ten potential HRE sites were identified according to the consensus sequence (A/G)CGTG. In order to pinpoint the functional HRE, we made seven serial deletion constructs and performed reporter assays to determine the effect of the deletions on reporter gene activity ( Figure 3B ). We found that a 113 bp fragment that harbors a HRE is responsible for the robust induction of mir-210 promoter under hypoxia. Mutation of this HRE site completely abolished the responsiveness of the promoter to HIF1a ( Figure 3C ). The promoter assay also confirmed that mir-210 is a HIF1a-dependent gene and is not HIF2a responsive.
Interestingly, when the human, mouse, rat, and dog mir-210 genomic sequences were compared, the mir-210 coding sequence and this HRE site are the only highly conserved sequences across species ( Figure 3C ), indicating the functional importance of the HRE.
We next wanted to determine if HIF1a is capable of binding to the mir-210 promoter directly in vivo. We designed two pairs of primers for chromatin immunoprecipitation (ChIP). The first pair flanks the functional HRE identified through serial deletion, while the other is approximately 500 bp upstream of this HRE as a control. We found that HIF1a specifically binds to the functional HRE, but not the control promoter sequence ( Figure 3D ).
mir-210 Is Hypoxia Regulated In Vivo
We hypothesized that if mir-210 is such a robust hypoxia-regulated gene in cell lines in vitro, we should be able to detect its increased expression in primary tumors that exhibit significant levels of hypoxia. We took advantage of the microarray profiling data in 65 primary head and neck tumor samples developed at the M.D. Anderson Cancer Center. First, we performed a whole-genome unsupervised clustering analysis based on the gene expression profiles and mir-210 expression in these samples. We found that expression of mir-210 is highly correlated with the expression of some well-known hypoxia-inducible genes, with the strongest correlation with NDRG1 and SLC2A1 (GLUT1) (Figures S2A and S2C) . Interestingly, two genes in the list, HRAS and RASSF7, are not known for to be hypoxia-inducible genes. However, they are both located on chromosome 11p15.5 and are proximally adjacent to mir-210 ( Figure S2D ), suggesting that their expression may be coordinated due to genomic proximity. Next, we compared mir-210 expression with a list of ten overlapping genes from two published studies describing a hypoxic gene expression signature in these 65 primary head and neck tumor samples (Chi et al., 2006; Winter et al., 2007) . We found that expression of mir-210 is closely correlated with that of these ten genes ( Figure S2B ). Since these ten genes are obtained from two independent studies, they may represent a core gene set regulated by hypoxia in general, and therefore the close correlation of mir-210 expression to their expression strongly suggests that mir-210 is a hypoxia-regulated gene in vivo.
Direct Identification of mir-210 Target Genes through Argonaute 2 Ribonucleoprotein Immunoprecipitation
It has been known that miRNA could regulate its target genes by inhibiting protein translation and/or degrading messenger RNAs (Jackson and Standart, 2007; Nilsen, 2007) . Since miRNA regulates its target genes through an imperfect match in their 3 0 UTR region, and only a six to seven nucleotide perfect match in the ''seed'' region is required, each miRNA could potentially regulate hundreds of target genes as predicted by computational programs. However, many of them may just be artifacts. Therefore, currently it is still a major challenge to directly identify miRNA target genes. We hypothesized that miRNA functions through the argonaute protein complex and that immunoprecipitation of the major functional component of this complex, AGO2, would be useful to identify mRNAs associated with AGO2 using microarrays. Thus, the combination of experimentally identified genes with computational predictions would be a powerful approach to identify mir-210 targets. Our experimental design is illustrated in Figure 4A . The N terminus of the AGO2 protein was labeled with a c-myc tag, and a stable cell line with tagged AGO2 was established in MCF10A cells because of its robust mir-210 induction under hypoxia (Figure 2A and Figure S3 ).
After ribonucleoprotein immunoprecipitation (miRNP-IP) and microarray experiments, 246 genes with a higher than 2-fold enrichment in both array 1 and array 2 were selected. We then searched TargetScan, PicTar, mirRanda, and PITA programs compiling a list of 2754 potential mir-210 target genes (John et al., 2004; Kertesz et al., 2007; Krek et al., 2005; Lewis et al., 2005) . Fifty of the 246 genes (20.3%) are computationally predicted to be mir-210 targets ( Figures 4B and 4C) . Therefore, the 3 0 UTR mir-210 target sites were greatly enriched in the genes identified through the miRNP-IP approach. Interestingly, except EFNA3, none of the other identified genes are known to be induced by hypoxia. On the basis of functional annotation, genes involved in regulating gene expression and cellular metabolic process were strongly overrepresented among this set of 50 genes (p < 7.2 3 10 À5 and p < 1.2 3 10 À4 , respectively) ( Table S1 ), suggesting that mir-210 may downregulate genes expressed under normoxia when induced by HIF to better prepare cells to adapt and survive the hypoxic stress.
Validation of mir-210 Target Genes Identified through miRNP-IP
In order to validate mir-210 target genes identified through the RNA-IP approach, we cloned the 3 0 UTRs of four randomly selected genes with different degrees of enrichment into pGL3 vector to perform reporter assays. When the mir-210 expression plasmid was cotransfected into the cell with these reporter constructs, luciferase activity was repressed more than 50% in HOXA1 construct, 35% in HOXA9, 15% in PIM1, and 17% in TP53I11 constructs compared to cotransfection with pcDNA3.1 control plasmid ( Figures 5C-5F ). However, when a pGL3-Promoter control luciferase reporter construct and a CTGF 3 0 UTR construct without mir-210 target sequences were cotransfected, there was no repression of luciferase activity ( Figures 5A and 5B) . When a mir-210-expressing plasmid with mutated seed sequence was cotransfected, the repression of luciferase activity was completely abolished ( Figures 5C and 5D ).
In addition to these four genes we selected from the 50 gene list, one gene, FGFRL1, also caught our attention because of the presence of multiple mir-210 target sites in its 3 0 UTR region. It has been reported that closely located multiple miRNA target sites in a gene's 3 0 UTR region may function synergistically in mediating miRNA translation repression (Grimson et al., 2007; Rajewsky, 2006) . There are seven potential mir-210 target sites in the 3 0 UTR of FGFRL1, the highest number of predicted mir-210 target sites in a gene's 3 0 UTR, although none of them are well conserved across species ( Figure S4 ). We cloned a 1 kb fragment of the 3 0 UTR of FGFRL1 that contains all seven predicted mir-210 target sequences into a pGL3-Promoter vector and performed reporter assays. When the mir-210 expression plasmid was cotransfected into the cell with FGFRL1 3 0 UTR luciferase reporter construct, reporter luciferase activity was repressed more than 90% compared to cotransfection with pcDNA3.1 control plasmid ( Figure 5G ). However, the repression was completely abolished when a mutant form of mir-210 expressing plasmid was cotransfected. Taken together, our data show that HOXA1, FGFRL1, and HOXA9 are robust mir-210 target genes, suggesting that approximately 60% of the targets we identified through miRNP-IP experiments are real mir-210 targets, a number of which is consistent with the accuracy of miRNP-IP approach in identifying miRNA targets reported elsewhere (Karginov et al., 2007) . Therefore, when combined with computational prediction, miRNP-IP is an efficient means to identify miRNA targets.
Expression of mir-210 Represses Tumor Xenograft Growth
In order to elucidate the biological function of mir-210, we stably expressed mir-210 in a head and neck cancer cell line, FaDu, and a pancreatic cancer cell line, SU86.86, by retroviral transduction. The ectopic expression of mir-210 is comparable to that found under hypoxic conditions ( Figure S5A ). Although when exposed under 2% oxygen the cells ectopically expressing mir-210 had an even higher mir-210 level than that of parental cells under the same condition, their mir-210 level is still comparable to the hypoxic mir-210 expression in some other cell lines in the same type of cancer ( Figure S5B ). Expression of mir-210 did not affect cell growth under normoxia or 2% oxygen conditions ( Figure S6 ). However, when these two cell lines that stably express mir-210 were subcutaneously implanted into nude mice, tumor growth was significantly delayed (Figures 6A and 6B) . Sections of individual tumors were stained with antibodies to CD31, Ki67, and TUNEL to examine angiogenesis, proliferation, and apoptosis, respectively. Interestingly, it appeared that mir-210 expression had little effect on any of the processes, in agreement with our in vitro assay. However, in mice implanted with FaDu cells ectopically expressing mir-210, five out of seven mice did not have measurable tumors until week 4, compared to one out of six in the control group ( Figure 6C ). In mice implanted with SU86.86 cells ectopically expressing mir-210, three out of five mice did not have measurable tumors until week 6, compared to none in the control group ( Figure 6D) .
Interestingly, although the initiation of xenograft growth was severely delayed in mice implanted with cells ectopically expressing mir-210, these tumors eventually overcome this inhibitory effect and start to grow. It is possible that the growth of these tumors may be due to loss of mir-210 expression or utilization of alternative pathways to circumvent mir-210's inhibitory effect. To distinguish these two possibilities, we measured mir-210 expression in harvested FaDu tumor samples ( Figure 6E gesting that the tumor cells utilized both means to overcome mir-210's inhibition on tumor growth initiation. Since mir-210 showed a clear inhibitory effect on tumor growth initiation, we analyzed the sizes of harvested xenograft samples and their corresponding mir-210 expression levels. As shown in Figure 6F , there is a statistically significant negative correlation between FaDu xenograft size and mir-210 expression level (r = À0.58, p = 0.0367), indicating mir-210 expression is growth inhibitory. Taken together, our data indicate that ectopic expression of mir-210 is primarily inhibiting initiation of tumor growth, since a significantly higher mir-210 expression still remains in these growing tumors whose growth was inhibited initially.
HOXA1 Is a mir-210 Target In Vivo
In an effort to investigate if the mir-210 targets we identified are also regulated by mir-210 in vivo, we examined HOXA1 protein level in harvested tumor xenograft samples ( Figure 7A ). HOXA1 protein level is generally higher in xenograft samples with lower mir-210 expression in each group. The two samples (numbers six and seven) with lowest mir-210 expression in mir-210-derived xenograft tumors also had the highest expression of HOXA1 in this group, and in the parental group the sample (number one) with highest mir-210 expression had the lowest expression of HOXA1, suggesting that HOXA1 is a mir-210 target in vivo.
Rescuing mir-210 Phenotype by HOXA1 and FGFRL1 in Tumor Xenograft Because miRNA binds to the 3 0 UTR region of its target gene to repress protein translation or cause degradation of mRNA, we tested if the protein-coding regions of two top candidate genes, HOXA1 and FGFRL1, that are identified by miRNA-IP approach and validated by reporter assays could rescue the phenotype caused by ectopic expression of mir-210. We also included a gene, PIM1, that is not a mir-210 target as a control. The protein-coding regions of HOXA1, FGFRL1, and PIM1 were cloned and stably expressed in FaDu cells expressing mir-210 ( Figure S7 ). The resulting cells were subcutaneously implanted into nude mice, and the growth of tumors derived from these cells was compared to parental cells and cells ectopically ex- pressing mir-210. We found that the inhibitory effect elicited by mir-210 on tumor growth initiation was rescued in part by expressing either HOXA1 or FGFRL1, but not by PIM1 (Figures 7B and 7C ). However, neither gene could completely rescue the phenotype, suggesting that more than one target gene is involved in inhibiting tumor growth initiation by mir-210. This is not surprising, given that miRNAs regulate the expression of groups of genes and that we identified other potential mir-210 targets as well in this study.
DISCUSSION
Since the discovery of first miRNA in 1993, the role miRNAs play in gene regulation has increasingly been appreciated, especially in recent years (Bartel, 2004; Lee et al., 1993) . In this study, we utilized microarray technology to identify mir-210 as the predominant miRNA induced by hypoxia, in agreement with what other groups have reported recently (Camps et al., 2008; Giannakakis et al., 2008; Kulshreshtha et al., 2007) . However, in these previously published reports, the structure of mir-210 promoter has not been analyzed, and the HRE responsible for the robust mir-210 hypoxia induction has not been identified. By constructing a series of mir-210 promoter deletion constructs, we identified a functional HRE and demonstrated that its hypoxia induction is HIF1a specific and is not regulated by HIF2a. Interestingly, the HRE we identified and the mir-210 coding sequence are the only loci in the mir-210 genomic region highly conserved across species, which strongly suggests the functional importance of this HRE and the unique and critical role hypoxia plays in regulating mir-210 expression.
Recently, it has been reported that HIF1a binds to two predicted HRE sites upstream of the one we identified by ChIP assay (Kulshreshtha et al., 2007) . Since in our study a different HRE that is functional was identified through serial deletions of mir-210 promoter, it is possible that HIF1a binds to HRE sequences whenever the binding sites are physically available, but binding of HIF1a to HRE does not necessarily results in active transcription of its target genes. Other cofactors need to be recruited to cooperate with HIF1a to initiate transcription, which may be determined by surrounding genomic sequences that provide binding sequence for additional cofactors.
Because mir-210 is such a robustly induced gene under hypoxia in vitro, we took an unbiased approach to assess whether expression of mir-210 could reflect tumor hypoxia in vivo. Using an unsupervised clustering analysis, we found that mir-210 expression highly correlated with well-characterized hypoxia-regulated genes in primary head and neck tumor samples. In addition to the four well-known hypoxia-inducible genes highlighted in Figure S4C , the other two genes, AK3L1 and ITGB4, have also been reported as hypoxia regulated (Elvidge et al., 2006; Martin-Rendon et al., 2007) . This indicates that expression of mir-210 could potentially serve as a surrogate marker for tumor hypoxia in vivo. Interestingly, mir-210 has been found overexpressed in several tumor types (Volinia et al., 2006) .
Overexpression of mir-210 has been detected in breast cancer patients recently and was correlated with worse prognosis and was also found correlated to VEGF, hypoxia, and angiogenesis (Camps et al., 2008; Foekens et al., 2008; Zhang et al., 2009) . In these reports, the expression of mir-210 may actually reflect the hypoxic status of those tumor samples instead of its biological function in tumorigenesis. Therefore, overexpression of mir-210 could predict poor prognosis in these cases, maybe because mir-210 is a surrogate marker for tumor hypoxia, which is a well-known independent indicator of poor patient outcome (Vaupel and Mayer, 2007) .
In an effort to experimentally identify mir-210 target genes, we used a miRNP-IP approach that has been successfully used to identify miRNA targets (Beitzinger et al., 2007; Easow et al., 2007; Karginov et al., 2007) . MiRNP-IP is particularly suited to identify mir-210 targets because induction of mir-210 expression and enrichment of its target mRNAs in the argonaute complex are all under physiological conditions and therefore, eliminate the requirement to transfect miRNA into cells that may cause experimental artifacts. Fifty genes with at least 2-fold enrichment were identified to be potential mir-210 targets, consistent with recent discoveries that miRNAs regulate the protein output of a large number of genes and that even one single miRNA could affect the expression of hundreds of genes (Baek et al., 2008; Selbach et al., 2008) . Since several other miRNAs are also hypoxia inducible (Kulshreshtha et al., 2007) (Figure S1 ) the 50 genes in the list may include their targets as well. This may explain why the PIM1 and TP53I11 genes are enriched by microarray analysis but the 3 0 UTR reporter assays only demonstrate a weak repression by mir-210. Alternatively, they may represent the intrinsic limitation of this approach in identifying miRNA targets because the similar efficiency (70% versus 60% in the current study) was reported in an independent study (Karginov et al., 2007) . Interestingly, we observed that the majority of the 50 genes are not known to be hypoxia inducible. This suggests activation of two parallel pathways by HIF1a when cells are under hypoxic stress. The first pathway is well-studied and is directly regulated by HIF1a transcriptionally, and includes genes involved in glycolysis and angiogenesis. Genes induced in this pathway are necessary for cells to survive or adapt to hypoxic stress. The second pathway is indirectly regulated by HIF1a through the induction of mir-210. We hypothesize that steady expression of the genes in this second pathway are necessary for cells under a normoxic environment but must be inhibited under hypoxic conditions. This is supported by gene ontology (GO) analysis that 19 of the 50 mir-210 target genes are involved in regulation of cellular metabolic processes and gene expression. Thus, the mir-210 miRNA pathway functions as a rheostat, allowing cells to quickly and efficiently turn off or tune down the protein output of dozens of genes under hypoxia. One exception is the EFNA3 gene identified in our miRNP-IP experiment, whose expression is highly induced under hypoxia. Cells may utilize mir-210 to fine-tune EFNA3 expression, as EFNA3 has recently also been reported as a mir-210 target by other groups (Fasanaro et al., 2008; Pulkkinen et al., 2008) .
Interestingly, ectopic expression of mir-210 delayed subcutaneous tumor growth, and the expression level of mir-210 in harvested tumor xenograft samples negatively correlated with tumor size. This was a surprising result because HIF1a is generally considered a promoter of tumorigenesis, although some published data suggest it can also inhibit tumor growth (Carmeliet et al., 1998; Maranchie et al., 2002; Raval et al., 2005) . HIF1a has been well known to regulate a variety of downstream target genes, including those involved in angiogenesis, glycolysis, and glucose transport, such as VEGF, PGK, and GLUT1. However, HIF1a also induces genes leading to cell-cycle arrest and cell death, such as p21, p27, and NOXA (Gardner et al., 2001; Goda et al., 2003; Green et al., 2001; Kim et al., 2004) . The functional balance between these pro-and antitumorigenesis genes regulated by HIF1a may determine the tumor-promoting or tumor-suppressing phenotypes observed previously under different circumstances. To tease out how each HIF1a target gene contributes to this overall phenotype, individual genes need to be studied.
Analyzing mir-210 expression in harvested tumor samples suggests that ectopic expression of mir-210 only affects the initiation phase of tumor growth, since a significantly higher mir-210 expression still remains in these growing tumors whose growth was inhibited initially. In tumors with ectopic mir-210 expression, the three smallest tumors also have the highest mir-210 expression, further demonstrating that the ectopic expression of mir-210 accentuates the inhibitory function of this microRNA on tumor initiation. However, once tumor cells transit through the initial inhibitory effect of mir-210, they start to grow in a similar manner as their parental cells. In agreement with our findings, the mir-210 genomic region has been shown to be deleted and its expression lost at a high frequency in ovarian cancer (Giannakakis et al., 2008) , suggesting a potential tumor suppressor function of mir-210. Interestingly, mir-210 was recently shown to promote cell-cycle progression by activating c-Myc through inhibiting MNT, an antagonist of c-Myc and a gene ranked second in our 50 gene list (Zhang et al., 2009 ). However, in our systems we did not observe an in vitro growth advantage of cells ectopically expressing mir-210, and in vivo mir-210 actually repressed tumor growth initiation.
In our miRNP-IP experiment, several oncogenes were identified as potential mir-210 targets, such as HOXA1 (Zhang et al., 2003) . It is plausible that by downregulating oncogenes through ectopic expression of mir-210, the initiation of tumor growth may be temporarily impaired, providing tumor cells time to adapt to a hypoxic environment. Our rescue experiment by implanting cells expressing the HOXA1 gene without a 3 0 UTR on a mir-210-expresing background provides evidence to support this hypothesis. When HOXA1 protein levels were examined in the harvested xenograft tumor samples, they had the opposite profile of mir-210 expression, confirming that HOXA1 is a mir-210 target in vivo. However, HOXA1 protein was also upregulated in parental tumors (numbers three through six), although they all have slightly increased mir-210 expression (1.2, 1.6, 2.1, and 1.1, respectively) compared to parental input mir-210 expression, suggesting factors other than mir-210 control HOXA1 expression and its importance in tumorigenesis.
In summary, our work identified mir-210 as a robust hypoxiainducible miRNA regulating a number of genes that are not induced under hypoxia. Our finding reveals a new mechanism of gene regulation by HIF1a through a miRNA pathway and therefore sheds new light on the complexity of hypoxia gene regulation. More importantly, ectopic expression of mir-210 repressed tumor growth initiation, and thus mir-210 may account for at least part of the repressive effect of HIF1a on tumor growth previously observed.
EXPERIMENTAL PROCEDURES
Reporter Assay All transfections were carried out using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Luciferase activity was measured using the Dual Luciferase Assay System (Promega) according to the manufacturer's instructions.
Quantitative RT-PCR Hsa-mir-210 and endogenous control RNU48 TaqMan Quantitative RT-PCR (QRT-PCR) kits were purchased from Applied Biosystems (Foster City, CA). The RT and TaqMan quantitative PCR were performed according to the manufacturer's instruction. Expression level of FGFRL1 and PIM1 was measured by qPCR using a SYBR Green PCR master mix (Applied Biosystems). Primer sequences are available upon request.
In Vivo Experiments
Five-to six-week-old male nude mice supplied by Charles Rivers were housed in the AALAC-approved Stanford University Animal Facility with 12 hr light cycles. Food and water were provided ad libitum. All experimental protocols were APLAC approved. Cells were injected subcutaneously (s.c.) on the backs of mice. Tumors were measured every 3 days, and tumor volume was calculated by the following formula: (W2 3 L) 3 0.52 (W, width; L, length). Tumors were frozen in OCT and 5 mm sections were cut.
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